Skip to main content
32 search results for:

Sodium-glucose transporter-2 inhibitors 

sort by |
"newest" sorts results by publication date. "most relevant" also considers factors like how often the search phrase is in the result.
  1. 11-22-2017 | Cardiovascular disorders | Editorial | Article

    Diabetes in special situations: Sodium-glucose co-transporter-2 inhibitors in acute coronary syndrome

    Editorial Board member Sanjay Kalra presents a pragmatic approach to the use of sodium-glucose co-transporter-2 inhibitors in patients affected by acute coronary syndromes.

  2. 06-23-2018 | Heart failure | Article

    Association between sodium glucose co-transporter 2 inhibitors and a reduced risk of heart failure in patients with type 2 diabetes mellitus: A real-world nationwide population-based cohort study

    Kim YG et al. Cardiovasc Diabetol 2018; 17: 91. doi: 10.1186/s12933-018-0737-5

  3. 03-25-2018 | SGLT2 inhibitors | Article

    Sodiumglucose co‐transporter2 inhibitors as add‐on therapy to insulin for type 1 diabetes mellitus: Systematic review and meta‐analysis of randomized controlled trials

    Yamada T et al.  Diabetes Obes Metab 2018; Advance online publication. doi: 10.1111/dom.13260

  4. 12-01-2014 | SGLT2 inhibitors | Review | Article

    Sodium glucose cotransporter-2 inhibitors: A review of their basic and clinical pharmacology

    Kalra S.  Diabetes Ther 2014; 5: 355–366. doi: 10.1007/s13300-014-0089-4

  5. 08-09-2017 | SGLT2 inhibitors | News | Article

    Support for cardioprotective effects of SGLT2 inhibitors

    Patients with type 2 diabetes receiving treatment with sodium-glucose co-transporter-2 inhibitors have a lower risk for adverse cardiovascular outcomes than those using other glucose-lowering drugs, results from the CVD-REAL Nordic study suggest.

  6. 02-27-2018 | SGLT2 inhibitors | Article

    SGLT-2 inhibitors and the risk of infections: A systematic review and meta-analysis of randomized controlled trials

    There is concern about the infection-related safety profile of sodiumglucose co-transporter 2 (SGLT-2) inhibitors.

  7. 09-14-2017 | SGLT2 inhibitors | EASD 2017 | Article

    Latest CVD-REAL data bolster cardioprotective effects of SGLT2 inhibition

    The CVD-REAL investigators have presented further results demonstrating the effects of sodium-glucose co-transporter 2 inhibitors on cardiovascular outcomes in real-world clinical practice.

  8. 12-01-2017 | SGLT2 inhibitors | Article

    Effectiveness of long-term treatment with SGLT2 inhibitors: Real-world evidence from a specialized diabetes center

    Sodium-glucose co-transporter 2

  9. 09-30-2016 | SGLT2 inhibitors | Article

    Combination therapy with glucagon-like peptide-1 analogues and sodium-glucose cotransporter-2 inhibitors in the management of diabesity: the real world experience

    Diabesity—obesity resulting in diabetes—is a major health problem globally because of the obesity epidemic.

  10. 09-30-2016 | Obesity | Article
    Endocrine

    Combination therapy with GLP-1 analogues and SGLT-2 inhibitors in the management of diabesity: The real world experience

    Diabesity—obesity resulting in diabetes—is a major health problem globally because of the obesity epidemic.

  11. 03-27-2018 | Nephropathy | Review | Article

    New diabetes therapies and diabetic kidney disease progression: The role of SGLT-2 inhibitors

    Purpose of Review: Sodium-glucose co-transporter 2 (SGLT-2) inhibitors have emerged as a promising drug class for the treatment of diabetic kidney

  12. 11-01-2017 | Diagnosis | Case study | Article

    Atypical diabetes: Case study 2

    The second case study in our series on atypical forms of diabetes from Jay Shubrook presents a highly distinct variation of the disease and challenges you to make the correct diagnosis.

  13. 06-29-2020 | SGLT2 inhibitors | News | Article

    CVD-REAL 2 data support cardiovascular benefits of SGLT2 inhibitors

    The latest CVD-REAL 2 data confirm clinical trial findings by showing that SGLT2 inhibitors significantly lower cardiovascular disease risk in people with type 2 diabetes, this time in comparison with DPP-4 inhibitors.

  14. 08-18-2020 | SGLT2 inhibitors | News | Article

    African Americans have high cardiometabolic risk pre- and post-SGLT2 inhibitor initiation

    Among people with type 2 diabetes, those of African American descent have a higher cardiometabolic risk factor burden than Caucasians at the time of starting treatment with a SGLT2 inhibitor and this might affect long-term treatment response, study findings suggest.

  15. 09-05-2018 | Diagnosis | Case study | Article

    Acute illness while on a SGLT2 inhibitor and ketogenic diet

    Advisory Board member Theresa Smyth tackles an emergency case in a type 2 diabetes patient treated with empagliflozin. What went wrong and how should he be managed?

  16. 03-15-2017 | Heart failure | Review | Article

    Promise of SGLT2 inhibitors in heart failure: Diabetes and beyond

    This review describes the effects of sodium-glucose transporter-2 inhibitors with particular emphasis on improvement of cardiovascular function.

  17. 05-24-2018 | Diet | Article

    The effect of Ramadan fasting and continuing sodium-glucose co-transporter-2 (SGLT2) inhibitor use on ketonemia, blood pressure, and renal function in Muslim patients with type 2 diabetes

    Shao Y et al. Diabetes Res Clin Prac 2018. doi: 10.1016/j.diabres.2018.05.022

  18. 02-08-2018 | Cardiovascular outcomes | News | Article

    Further support for cardiovascular benefits of canagliflozin

    Results of a US database study suggest that the sodium-glucose co-transporter-2 inhibitor canagliflozin is associated with a lower risk for heart failure hospitalization compared with three other classes of antidiabetes agent.

  19. 02-19-2016 | Hyperglycemic hyperosmolar state | Review | Article

    Diabetic emergencies: Ketoacidosis, hyperglycemic hyperosmolar state, and hypoglycemia

    In addition, an association has been reported between the use of sodiumglucose co-transporter 2 (SGLT2) inhibitors (a class of oral antidiabetic agents that decrease concentrations of plasma glucose by inhibiting proximal tubular reabsorption in the kidney) and the development of DKA among patients with T1DM and T2DM 24, 25 .

Filter search results

Search Operators:

„ ... ... “ Finds documents with exactly this word group, in exactly this word order and spelling (e.g., "employer branding").
AND Finds documents with both search terms (e.g., sales AND bonus).
OR Finds documents with one or the other search term (e.g., porsche OR volkswagen).
Blank Space Finds documents with all search terms. Blank space is understood as AND (e.g., man robot production).
NOT Finds documents with no appearance of the word behind NOT (e.g., ford NOT "harrison ford").
COUNT(...)>n Finds documents where the search term is mentioned at least "n" times."n" may be any number (e.g., COUNT(gear)>8).
NEAR(..., ..., ) Finds documents with both search terms in any word order, permitting "n" words as a maximum distance between them. Best choose between 15 and 30 (e.g., NEAR(recruit, professionals, 20)).
* Finds documents with the search term in word versions or composites. The star * marks whether you wish them BEFORE, BEHIND, or BEFORE and BEHIND the search term (e.g., lightweight*, *lightweight, *lightweight*).
? Finds documents with the search termn in different spellings."?" allows only one character (e.g., organi?ation).
& + - Special characters are understood as AND (e.g., Miller Bros. & Sons).

You can use operators in your search query to narrow down your results even more.

Tap the operator, or hover the mouse pointer over it, to read more about how it works.